missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human GNB4 (aa 250-278) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (100%), Rat (100%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-83512 (PA5-83512. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Heterotrimeric guanine nucleotide-binding proteins (G proteins), which integrate signals between receptors and effector proteins, are composed of an alpha, a beta, and a gamma subunit. These subunits are encoded by families of related genes. This gene encodes a beta subunit. Beta subunits are important regulators of alpha subunits, as well as of certain signal transduction receptors and effectors.
Specifications
Specifications
| Accession Number | Q9HAV0 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 59345 |
| Name | Human GNB4 (aa 250-278) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 6720453A21Rik; CMTD1F; G protein beta-4 subunit; G protein subunit beta 4; G(beta)4; gbb4; Gnb4; G-protein beta 4 subunit; guanine nucleotide binding protein (G protein), beta 4; guanine nucleotide binding protein (G protein), beta polypeptide 4; guanine nucleotide binding protein beta 4 subunit; guanine nucleotide binding protein, beta 4; guanine nucleotide-binding protein subunit beta-4; Transducin beta chain 4 |
| Common Name | GNB4 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction